Martell Diagnostic Laboratories, Inc. was formed to improve the management of cancer and advance exciting new technologies and solutions. Our commercial business model revolves around establishing a Minnesota-based national reference laboratory.
The first “product” is a blood test to monitor the course and treatment of HER2 breast cancer, the most aggressive form responsible for the majority of deaths. We recently began promoting HERTEST®, a branded version of the sHER2/neu ELISA test. In addition, we are commercializing CHECKMARK®, a blood test (serum) to measure soluble PD-L1, a biomarker of prognostic value in the management of lung, kidney and other cancers. We are developing ways to take these tests to the doctor’s office or hospital--this will be accomplished using laminar flow assays (LFA).